From Yahoo Finance: 2025-05-24 03:55:00

Redburn Atlantic upgraded Charles River Laboratories International, Inc. (NYSE:CRL) from “Neutral” to “Buy” with a price objective of $182. The upgrade was driven by improved demand in the Discovery and Safety Assessment business, Elliott Management’s investment, and a strategic review. The stock currently trades at a 36% discount to its historical forward multiple.

Charles River Laboratories International, Inc. (NYSE:CRL) is positioned for growth with its leading market position and expected demand normalization. The company’s Q1 2025 report showed signs of improved demand, particularly in DSA booking activity. CRL focuses on advancing scientific innovation and enhancing efficiency in drug development programs.

CRL provides drug discovery, non-clinical development, and safety testing services. While the stock has growth potential, some believe other AI stocks offer greater returns with lower risk. For those seeking AI investments, consider exploring opportunities beyond CRL. Check out reports on promising AI stocks with significant upside potential.

For more insights on AI stocks and growth opportunities, explore reports on 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now. Disclosure: None.

Read more: Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT